➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
Baxter
McKesson
Moodys

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRAVOPROST

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Travoprost

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00670033 Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 2 2008-04-01 The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension.
New Formulation NCT01452009 Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004% Withdrawn Alcon Research Phase 3 2011-11-01 A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%
New Formulation NCT01658839 Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients Completed Alcon Research Phase 1 2013-01-01 The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Travoprost

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00051142 A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Completed Alcon Research Phase 3 2001-02-01 The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
NCT00051181 A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma Completed Alcon Research Phase 3 2000-01-01 To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
NCT00121147 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Alcon Research N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00121147 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Hermann Eye Center N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00308945 Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients Completed University Hospital, Basel, Switzerland Phase 4 2003-11-01 Vasoactivity of topical drugs may be of prognostic relevance in glaucoma. There is very little information for a major class, the prostaglandin analogues with regard to this aspect. The purpose of this study is to compare the effect of travoprost 0.004% and latanoprost 0.005% on choroidal blood flow and retinal vascular diameter in glaucoma patients. After washout of current topical medication, intraocular pressure (IOP) in both eyes (Goldmann applanation tonometry), choroidal blood flow (laser Doppler flowmetry) and retinal vessel diameter (Retinal Vessel Analyzer) in one randomly selected eye will be measured at baseline, after two weeks and after 4 weeks of treatment with travoprost or latanoprost QD, in a randomized, double masked 2-way cross-over study in 20 open angle glaucoma patients.
NCT00331240 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination Completed Aristotle University Of Thessaloniki Phase 3 2006-03-01 The purpose of this study is to compare the short-term (8 week) mean 24-hour intraocular pressure control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given once in the morning with placebo once in the evening in patients with open-angle glaucoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Travoprost

Condition Name

Condition Name for Travoprost
Intervention Trials
Ocular Hypertension 59
Glaucoma 39
Open-angle Glaucoma 23
Open Angle Glaucoma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Travoprost
Intervention Trials
Glaucoma 78
Ocular Hypertension 67
Glaucoma, Open-Angle 54
Hypertension 50
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Travoprost

Trials by Country

Trials by Country for Travoprost
Location Trials
United States 103
Canada 6
Germany 3
Italy 3
Greece 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Travoprost
Location Trials
Texas 17
California 9
Ohio 5
Georgia 5
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Travoprost

Clinical Trial Phase

Clinical Trial Phase for Travoprost
Clinical Trial Phase Trials
Phase 4 55
Phase 3 18
Phase 2 12
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Travoprost
Clinical Trial Phase Trials
Completed 71
Recruiting 8
Terminated 5
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Travoprost

Sponsor Name

Sponsor Name for Travoprost
Sponsor Trials
Alcon Research 56
Glaukos Corporation 7
Allergan 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Travoprost
Sponsor Trials
Industry 83
Other 23
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Moodys
Express Scripts
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.